ImmunoPrecise Antibodies (IPA) said Monday that it has made a 'significant contribution' to an anti-aging study led by scientists at the Mayo Clinic.
The biotech firm said the study used its proprietary rabbit B Cell Select platform to isolate and generate antibodies that target phosphorylated ubiquitin, which is an indicator of mitochondrial damage.
"This study advances our understanding of how aging impacts mitochondrial health, a crucial factor in neurodegenerative diseases like Parkinson's and Alzheimer's," the company said.
Price: 0.6497, Change: -0.03, Percent Change: -4.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。